Biovica establishes DiviTum® TKa commercialization partnership in Italy
Biovica, active in cancer monitoring, today announces that the company has signed a commercial partnership agreement with the Italian company, IT Health Fusion, for the commercialization of the DiviTum® TKa assay in Italy.
In Italy, some 17,000 women are diagnosed with metastatic breast cancer every year. IT Health Fusion, which is a subsidary of the biotech and pharmaceutical company BIOVIIIx, will lead the Italian market introduction, where the initial focus will be on private insurance and out-of-pocket markets, together constituting some 40 percent of the Italian market.
“We are happy to have signed a partnership agreement with such a fast-moving team that has a successful track record of bringing healthcare products to market. Together we are ready to take on the important Italian market. It is one of the largest in the Europe, but also a market where we have strong KOL support,” said Helle Fisker, VP of Commercialization for Biovica.
“Bringing the DiviTum TKa assay to the Italian market is a perfect fit for our organization. BIOVIIIx and IT Health Fusion have the right connections at hospitals and among healthcare professionals, based on deep experience in the field of oncological pharmaceuticals,” said Davide Rosiello, CEO of IT Health Fusion and BIOVIIIx Group.
“The IT Health Fusion sales force of eight senior sales agents has connections in cancer diagnostic and monitoring departments. We are excited to start executing our launch activities for DiviTum TKa. Our experienced salespeople will guide the introduction of the test to help patients suffering from metastatic breast cancer. We are eager to get started,” said Fulvio Manzo, Sales and Marketing Manager of IT Health Fusion, in charge of the launch and rollout of DiviTum TKa in Italy.
About IT Health Fusion
IT Health Fusion is a new generation global healthcare company. The company’s mission is to reduce critical issues, and improve people’s health and wellbeing, the safety of health workers and the effectiveness of hospital processes to save more lives. IT Health Fusion does this with the design, installation and validation of new generation cleanrooms designed for personalized oncology therapies or as cell and tissue typing laboratories and with the marketing of a patented device/method for the automated preparation of therapies and systems for the governance of drug chain inside the hospital. IT Health Fusion has deep experience in the IVD market in Europe: oncology, anatomic pathology, infectious disease for Public and Private Hospitals. For more information, please visit: www.ithealthfusion.com
Biovica – Treatment decisions with greater confidence
Biovica develops and commercializes blood-based biomarker assays that help oncologists monitor cancer progression. Biovica’s assay, DiviTum® TKa, measures cell proliferation by detecting the TKa biomarker in the bloodstream. The assay has demonstrated its ability to provide insight to therapy effectiveness in several clinical trials. The first application for the DiviTum® TKa test is treatment monitoring of patients with metastatic breast cancer. Biovica’s vision is: “Improved care for cancer patients.” Biovica collaborates with world-leading cancer institutes and pharmaceutical companies. DiviTum® TKa has received FDA 510(k) clearance in the US and is CE-marked in the EU. Biovica’s shares are traded on the Nasdaq First North Premier Growth Market (BIOVIC B). FNCA Sweden AB is the company’s Certified Adviser. For more information, please visit: www.biovica.com
This information is information that Biovica International is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2023-04-04 08:00 CEST.
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
The _ga cookie, installed by Google Analytics, calculates visitor, session and campaign data and also keeps track of site usage for the site's analytics report. The cookie stores information anonymously and assigns a randomly generated number to recognize unique visitors.
This cookie is installed by Google Analytics.
A variation of the _gat cookie set by Google Analytics and Google Tag Manager to allow website owners to track visitor behaviour and measure site performance. The pattern element in the name contains the unique identity number of the account or website it relates to.
Installed by Google Analytics, _gid cookie stores information on how visitors use a website, while also creating an analytics report of the website's performance. Some of the data that are collected include the number of visitors, their source, and the pages they visit anonymously.
Hotjar sets this cookie to detect the first pageview session of a user. This is a True/False flag set by the cookie.
Hotjar sets this cookie to identify a new user’s first session. It stores a true/false value, indicating whether it was the first time Hotjar saw this user.
Hotjar sets this cookie to know whether a user is included in the data sampling defined by the site's pageview limit.
Hotjar sets this cookie to know whether a user is included in the data sampling defined by the site's daily session limit.